Business Context and Reporting Period
This Form 8-K was filed by Cerecor Inc. on September 22, 2016, reporting a material definitive agreement entered into on the same date. The filing details an exclusive license, development, and commercialization agreement with Eli Lilly and Company ("Lilly") for the compound LY3130481, now designated as CERC-611.
Key Financial Metrics
The filing does not provide standard financial statements, revenue, profit, cash flow, or debt metrics. The financial terms of the agreement are as follows:
- Upfront Payment: $2.0 million total ($750,000 due within 30 days; $1.25 million due after the first subject is dosed in a multiple ascending dose study).
- Milestone Payments: Up to $67.5 million in one-time development, commercialization, and sales milestones.
- Royalties: Mid-single digits to low double digits based on net sales of CERC-611.
Material Changes
The primary material change is the acquisition of exclusive, global rights to develop and commercialize CERC-611, a potent and selective TARP-γ8-dependent AMPA receptor antagonist. Cerecor retains exclusive rights even against Lilly, with the ability to grant sublicenses. Lilly retains rights only for internal, non-clinical research. Cerecor is obligated to use commercially reasonable efforts to develop and commercialize the asset at its own expense.
Outlook, Risks, and Contingencies
Management Commentary: The agreement allows Cerecor to expand its pipeline with a novel therapeutic candidate. The agreement will be filed as an exhibit to the Quarterly Report on Form 10-Q for the quarter ended September 30, 2016.
Termination and Risks: The agreement may be terminated if either party enters bankruptcy, commits an uncured breach, or challenges patents relating to the licensed technology. The term continues on a country-by-country and product-by-product basis until royalty obligations end.
Investor Verification Checklist
- Verify the exact timing of the $1.25 million milestone payment contingent on the first subject dosing in a multiple ascending dose study.
- Confirm the specific royalty percentage tiers (mid-single to low double digits) in the full agreement text.
- Review the upcoming Form 10-Q for the full text of the Exclusive License Agreement and any additional financial impact disclosures.
- Assess Cerecor's current cash position to determine if the $750,000 immediate payment and future development costs are covered by existing liquidity.